论文部分内容阅读
目的分析莫沙必利联合埃索美拉唑治疗反流性食管炎临床效果与安全性。方法选取2013年9月—2015年1月本院收治的反流性食管炎患者124例,根据治疗方式分为2组,实验组与对照组各62例。对照组给予铝碳酸镁联合莫沙必利治疗,实验组采用莫沙必利联合埃索美拉唑进行治疗,疗程均为2个月,治疗后比较2组临床疗效与各项生活质量指数及药安全性。结果治疗后实验组患者临床总有效率与生活质量相关指数明显高于对照组,差异有统计学意义(P<0.05);实验组不良反应率为6.45%,明显低于对照组的16.13%,差异有统计学意义(P<0.05)。结论莫沙必利联合埃索美拉唑治疗反流性食管炎临床疗效显著,可明显改善患者生活质量并提高安全性,值得临床广泛推广。
Objective To analyze the clinical efficacy and safety of mosapride combined with esomeprazole in the treatment of reflux esophagitis. Methods A total of 124 patients with reflux esophagitis treated in our hospital from September 2013 to January 2015 were divided into two groups according to the mode of treatment, 62 in each of the experimental and control groups. The control group was treated with aluminum magnesium carbonate combined with mosapride, and the experimental group was treated with mosapride and esomeprazole for 2 months. After treatment, the clinical efficacy, quality of life index, Drug safety. Results After treatment, the clinical total effective rate and quality of life index in the experimental group were significantly higher than those in the control group (P <0.05). The adverse reaction rate in the experimental group was 6.45%, which was significantly lower than that in the control group (16.13% The difference was statistically significant (P <0.05). Conclusion Mosapride combined with esomeprazole in the treatment of reflux esophagitis clinical significant effect, can significantly improve the quality of life of patients and improve safety, it is widely recommended in clinical.